Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000302:isolation & purification; D001379:Azathioprine / Q000627:therapeutic use; D002353:Carrier State; D002648:Child; D002675:Child, Preschool; D005260:Female; D005455:Fluorescent Antibody Technique; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D007111:Immunity, Cellular; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D007962:Leukocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000382:microbiology*; D009093:Mucus / Q000382:microbiology; D010614:Pharynx / Q000382:microbiology*; D011182:Postoperative Care; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D007507:Therapeutic Irrigation; D014184:Transplantation, Homologous
D000914:Antibodies, Viral; D007166:Immunosuppressive Agents; D001379:Azathioprine; D011241:Prednisone